Bank of Montreal Can Buys 8,257 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Bank of Montreal Can raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 230,153 shares of the specialty pharmaceutical company's stock after acquiring an additional 8,257 shares during the quarter. Bank of Montreal Can owned approximately 1.09% of ANI Pharmaceuticals worth $12,723,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. US Bancorp DE lifted its position in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares in the last quarter. KBC Group NV raised its holdings in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $166,000. HighTower Advisors LLC bought a new position in ANI Pharmaceuticals in the third quarter valued at approximately $222,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock worth $246,000 after purchasing an additional 412 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

Shares of ANIP traded up $0.01 during midday trading on Friday, reaching $69.21. 299,660 shares of the stock were exchanged, compared to its average volume of 270,846. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.48. The stock's 50 day simple moving average is $63.07 and its 200 day simple moving average is $59.36. The company has a market cap of $1.51 billion, a P/E ratio of -125.84 and a beta of 0.49. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Insider Activity

In related news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the transaction, the vice president now owns 80,145 shares of the company's stock, valued at approximately $5,526,799.20. This represents a 0.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 3,200 shares of company stock worth $197,792. 12.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ANIP shares. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price target on the stock. Guggenheim reiterated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. StockNews.com raised ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Finally, JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target on the stock. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $79.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.